Get the Stockscreener App
9.87
0.92%
0.09
After Hours:
9.76
-0.11
-1.11%
Amneal Pharmaceuticals Inc stock is traded at $9.87, with a volume of 1.43M.
It is up +0.92% in the last 24 hours and up +1.33% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$9.78
Open:
$9.82
24h Volume:
1.43M
Relative Volume:
0.90
Market Cap:
$3.10B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-14.50
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
-4.08%
1M Performance:
+1.33%
6M Performance:
+37.47%
1Y Performance:
+13.45%
1-Day Range:
$9.75
$9.98
1-Week Range:
$9.56
$10.30
52-Week Range:
$6.685
$10.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.87 | 3.05B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
143.26 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.88 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.20 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.63 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
432.69 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal Pharmaceuticals Highlights Innovation and Access to Medication to Treat Patients - WJLA
What analyst consensus says on Amneal Pharmaceuticals Inc. stockFed Meeting & Risk Managed Investment Entry Signals - newser.com
What moving averages say about Amneal Pharmaceuticals Inc.2025 Earnings Surprises & Daily Stock Trend Reports - newser.com
Why Amneal Pharmaceuticals Inc. stock is considered a top pickMarket Movement Recap & High Accuracy Buy Signal Tips - newser.com
How to manage a losing position in Amneal Pharmaceuticals Inc.2025 Retail Activity & AI Forecasted Stock Moves - newser.com
Will Amneal Pharmaceuticals Inc. see short term momentumWeekly Trading Summary & Weekly High Potential Stock Alerts - newser.com
What MACD and RSI say about Amneal Pharmaceuticals Inc.Oil Prices & Accurate Technical Buy Alerts - newser.com
Assessing Amneal Pharmaceuticals (AMRX) Valuation After BLA Submission and Eased Regulatory Risks - Sahm
What to expect from Amneal Pharmaceuticals Inc. in the next 30 daysJuly 2025 Closing Moves & AI Forecasted Stock Moves - newser.com
Will Amneal Pharmaceuticals Inc. stock benefit from automationVolume Spike & Safe Capital Growth Tips - newser.com
Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis - MSN
Amneal Pharmaceuticals Hits New 52-Week High of $10.67 - Markets Mojo
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Amneal’s (AMRX) Biosimilar XOLAIR Application Could Shape Its Specialty Pharma Ambitions - Sahm
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Will Amneal Pharmaceuticals Inc. price bounce be sustainable2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
When is the best time to exit Amneal Pharmaceuticals Inc.July 2025 Outlook & Weekly High Return Stock Opportunities - newser.com
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Biosimilar XOLAIR FDA Submission – Learn Why - Yahoo Finance
Technical analysis overview for Amneal Pharmaceuticals Inc. stockEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com
A Look at Amneal Pharmaceuticals’s Valuation After XOLAIR Biosimilar Submissions and Recent Analyst Upgrades - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Receives Hold (C) Rating from Weiss Ratings - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market - MSN
Amneal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - sharewise.com
Does Amneal Pharmaceuticals Still Offer Value After 36% Surge and New Product Approvals in 2025? - Sahm
Amneal Pharmaceuticals (NASDAQ:AMRX) Increases 6.9% This Week, Taking Three-year Gains to 420% - 富途牛牛
Amneal Pharmaceuticals, Inc. (AMRX) Rating Update: Analysts See 18.48% Upside Potential - DirectorsTalk Interviews
Measuring Amneal Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Selloffs & Low Volatility Stock Recommendations - newser.com
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - Nasdaq
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab) - Business Wire
Applying Wyckoff theory to Amneal Pharmaceuticals Inc. stockJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Amneal Pharmaceuticals Inc. stockEarnings Trend Report & Expert Approved Momentum Ideas - newser.com
Is it time to cut losses on Amneal Pharmaceuticals Inc.Quarterly Portfolio Review & Proven Capital Preservation Methods - newser.com
Using Python tools to backtest Amneal Pharmaceuticals Inc. strategies2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Sentiment analysis tools applied to Amneal Pharmaceuticals Inc.Portfolio Risk Summary & High Win Rate Trade Tips - newser.com
How to read the order book for Amneal Pharmaceuticals Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Will breakout in Amneal Pharmaceuticals Inc. lead to full recoveryGap Down & Comprehensive Market Scan Insights - newser.com
Amneal Pharmaceuticals Hits New 52-Week High of $10.43 - Markets Mojo
Is Amneal Pharmaceuticals Inc. stock cheap compared to fundamentalsEarnings Growth Report & Safe Entry Zone Identification - newser.com
Chart based exit strategy for Amneal Pharmaceuticals Inc.Market Volume Summary & Smart Investment Allocation Insights - newser.com
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
5.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):